B4GALT1 siRNA Oligomers for Metabolic and Vascular Marker Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies are inadequate for effectively managing metabolic and vascular disorders associated with elevated levels of insulin resistance, glucose, insulin, HbA1c, free fatty acids, fibrinogen, total cholesterol, LDL cholesterol, and triglycerides.

Innovation Solution

Development of siRNA oligomers targeting B4GALT1 to inhibit its expression and function, which are conjugated with ligand moieties and modified with 2′-F and 2′-Me modifications, and include phosphorothioate internucleoside linkages, to lower these metabolic and vascular markers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional small organic compounds are used to inhibit protein function, then the therapy can be administered, but the effectiveness is inadequate for managing metabolic and vascular disorders

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoiddisease management capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent replaces traditional small organic compound therapy with siRNA oligomer-based gene silencing technology. This substitution enables targeted inhibition of B4GALT1 gene expression, providing a more effective and versatile approach for managing metabolic and vascular disorders by addressing the root genetic cause rather than merely inhibiting protein function downstream.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent employs chemical modifications including 2′-F and 2′-Me modifications on the siRNA oligomers, along with phosphorothioate internucleoside linkages. These parameter changes in the molecular structure enhance the stability, nuclease resistance, and therapeutic effectiveness of the siRNA compounds, resolving the inadequacy of traditional therapies.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If siRNA oligomers with multiple modifications are developed, then therapeutic effectiveness improves, but manufacturing complexity increases

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidmanufacturing complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The siRNA oligomers are designed with specific segmentation of modified and unmodified nucleosides. The modifications (2′-F, 2′-Me, phosphorothioate linkages) are strategically placed at specific positions within the oligomer sequence, allowing for controlled synthesis and assembly. This segmentation approach enables systematic manufacturing while maintaining enhanced therapeutic effectiveness.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The siRNA oligomers effectively reduce elevated levels of insulin resistance and metabolic markers, improving insulin sensitivity and reducing the risk of vascular diseases.

Implementation Method 1

siRNA, antisense RNA, and micro-RNA are oligonucleoside/oligonucleotides that prevent the formation of proteins by gene-silencing

Methodology Applied

Scientific EffectRNA interference:

Implementation Method 2

include phosphorothioate internucleoside linkages, to lower these metabolic and vascular markers

Methodology Applied

Scientific EffectPhosphorothioate modification:

Data Source

PatentUS20260009036A1Inhibitors of expression and/or function

Publication Date: 2026.01.08 E THERAPEUTICS LTD

AI summary

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of vascular and/or metabolic diseases.